Dario Zujo

Zilia is a Canadian medtech company pioneering the field of oculomics—the use of the eye as a non-invasive window into systemic and neurological health. By combining advanced imaging, spectroscopy, and artificial intelligence, Zilia has developed a breakthrough platform capable of measuring metabolic biomarkers in the eye, starting with retinal oxygen saturation (ocular oximetry). Unlike traditional eye care technologies that focus primarily on detecting late-stage structural damage, Zilia’s technology provides real-time, quantitative insights into tissue metabolism, enabling earlier detection, improved risk assessment, and more personalized disease management. Its flagship device, Zilia Ocular, is the first retinal camera designed to measure oxygen saturation directly in the tissues of the eye fundus, unlocking new possibilities in ophthalmology, neurology, cardiology, and pharmaceutical research. Founded in 2017 and ISO 13485 certified, Zilia is building a scalable hardware-and-cloud platform designed for clinical, research, and pharmaceutical markets. By transforming the eye exam into a powerful metabolic assessment, Zilia aims to shift healthcare from reactive treatment to proactive, precision-based care—ultimately improving outcomes for millions of patients worldwide.